This research combines focused ultrasound and engineered genetic circuits to activate cancer immunotherapy directly within solid tumors. By locally triggering immune-stimulating cytokines such as IL-12, the approach aims to convert “cold” tumors into “hot” tumors while minimizing systemic toxicity, potentially expanding curative immunotherapy treatments to more cancer patients.

Rhabdomyosarcoma is a rare and aggressive childhood cancer that resists many treatments. This research investigates CAR T-cell therapy for solid tumors, focusing on blocking a secondary inhibitory receptor. Early findings suggest reduced immune cell exhaustion and improved tumor killing, offering hope for more effective therapies for children with limited treatment options.